Main Content

MBC Study

Study title

Phase 1B study to assess the safety, tolerability and clinical activity of Gedatolisib in combination with Palbociclib and either Letrozole or Fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (MBC)

  • Principal Investigator: Dr. Shou Ching Tang


This study is looking at the safety and tolerability of an experimental drug for women with metastatic or locally advanced recurrent breast cancer.

Who can participate

Those eligible to participate in this study include:

  • Women ages 18 years or older

For more information

  • Sandra Powe
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson MS 39216
    (601) 984-1965
  • IRB Number: 2018-0047